Rapid Micro Biosystems, Inc. (RPID) AI Stock Analysis

Rapid Micro Biosystems, Inc. develops products for detecting microbial contamination in pharmaceutical, medical device, and personal care manufacturing globally. Its core offering is the Growth Direct platform, which includes the Growth Direct system, proprietary consumables, lab information management system connectivity software, and customer support and validation services. This platform automates microbial quality control testing for biologics, vaccines, cell and gene therapies, and sterile injectables. Applications include environmental monitoring, water testing, bioburden assessment, and sterility release testing. The company also provides installation, verification, technical training, and ongoing technical support.

Between FY2021 and FY2025, Rapid Micro Biosystems increased revenue from $23.2M to $33.6M, delivering a 5-year revenue CAGR of 15.9%. Annual revenue growth was 19.7% in FY2025, following 24.6% in FY2024 and 31.4% in FY2023. Gross margin turned positive in FY2025 at 22.7%, up from -0.4% in FY2024 and -24.4% in FY2023. However, profitability remains deeply negative; operating margin was -141.1% in FY2025, with net income of -$47.1M and an EPS of -$1.07. For the trailing twelve months ended June 30, 2026, revenue stood at $35.2M with quarterly revenue growth of 10.9% year-over-year, while operating margin was -153.0% and EPS was -$1.11.

As of June 30, 2026, Rapid Micro Biosystems held $19.8M in cash and short-term investments against total debt of $23.5M, resulting in net debt of $3.7M. Total assets stood at $58.5M and shareholders' equity was $17.7M, with a current ratio of 2.55 and a debt-to-equity ratio of 1.32. In FY2025, operating cash flow was -$31.1M, free cash flow was -$31.9M, and capital expenditures were $850,000. Cash was also supplemented by $162,000 in share issuances.

RPID closed at $0.76 on October 16, 2026, representing a market capitalization of $38.3M and an enterprise value of $59.4M. The stock trades at a price-to-sales ratio of 1.1x and an EV-to-EBITDA of 0.8x, compared to a median price-to-sales of 4.1x and EV-to-EBITDA of 12.0x for its US-listed Healthcare peers. Over the past year, RPID fell 74.0%, while the S&P 500 (SPY) gained 16.8%. Over a 5-year period, the stock declined 95.5% versus an 83.0% gain for SPY. The stock trades 67.6% below its 200-day average.

All 5 analysts tracking RPID rate the stock as Strong Buy, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target of $5.75 sits 652.6% above the last close of $0.76. Over the last 4 quarters, the company delivered 0 EPS beats. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $39.3M and an EPS of -$0.94. For the next fiscal year, 4 analysts project revenue of $46.3M and an EPS of -$0.71. The next earnings date is November 6, 2026.

This page is an AI-written research summary of Rapid Micro Biosystems, Inc. (RPID). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RPID income statement, RPID balance sheet, RPID key metrics, RPID analyst forecast, RPID chart. See the RPID stock overview for the latest quote and news.